Evogliptin is an anti-diabetic agent that contains an active ingredient called Evogliptin. It belongs to the medication class known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It is used to treat type 2 diabetes mellitus. 

It is used to treat type 2 diabetes mellitus to improve glycemic control. It can be used alongside diet and exercise as a monotherapy or combined with metformin.

Take the Evogliptin as your physician advises. Take medicine at a fixed time. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

The most common side effects of Evogliptin are hypoglycemia, nausea, vomiting, diarrhea, headache, dizziness, fatigue, and upper respiratory tract infection. 

Serious side effects while taking Evogliptin are pancreatitis and allergic reactions. 

Do not consume Evogliptin if you are allergic to Desidustat or any of its ingredients in the medication. Avoid taking the medicine if you have severe ketosis, diabetic coma, pre-coma, and type 1 diabetes. Before taking this medicine, inform your doctor if you are pregnant, planning to get pregnant, or think you may be pregnant or are breastfeeding. Inform your doctor if you have acute pancreatitis or heart or kidney problems. 

Before starting the treatment, inform your doctor about all the underlying medical conditions. n. Do not stop the medicine until your doctor advises. Do not double-dose the medicine to make up for a forgotten dose. Do not breastfeed while taking Dibasic Calcium Phosphate + Magnesium Orotate. 

Caution should be exercised when administering Evogliptin to patients with kidney conditions, and the patient's condition should be closely monitored. It is not recommended to take medicine for end-stage renal impairment who require dialysis, as there is no clinical experience available. 

Before starting the treatment, inform your doctor about all the underlying medical conditions. Do not stop the medicine until your doctor advises. Do not double-dose the medicine to make up for a forgotten dose. Notify your doctor if you experience any serious side effects. Contact your doctor for more information. 

1. Alkem Laboratories Ltd; [Revised on 21st April 2020] [Accessed on 17th July  2023], Evogliptin.pdf (alkemlabs.com)
2. Dutta D et al., Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus; [Accessed on 17th July  2023] Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibito...: Indian Journal of Endocrinology and Metabolism (lww.com)

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.